NCT07782632Recruiting
Liver Volume Metrics for Predicting Immunotherapy Prognosis in Unresectable Hepatocellular Carcinoma
Prediction of Immunotherapy Prognosis in Patients With Unresectable Hepatocellular Carcinoma Based on Functional Liver Volume and Total Liver Volume: A Multicenter Retrospective Cohort Study
Source: ClinicalTrials.gov · Last updated 24 Aug 2026
Brief summary (registry, in English)
This multicenter retrospective cohort study aims to evaluate the prognostic value of functional liver volume and total liver volume in patients with unresectable hepatocellular carcinoma (HCC) undergoing immunotherapy. The study explores whether baseline liver volume metrics can effectively predict survival outcomes and treatment responses in this patient population to assist in clinical decision-making.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 467 (estimated)
- First submitted
- 20 Aug 2026
- Start date
- 1 Jan 2019
- Primary completion date
- 30 Dec 2026
- Lead sponsor
- Anhui Provincial Hospital
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07782632
What you commit to
- Study type: Observational
- Planned participants: 467
- From 1 Jan 2019 to the primary completion date, 30 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- \- Prior surgical resection or liver transplantation for HCC.
- Co-existence of other concurrent primary malignant tumor types.
Other
- Severe image artifacts or technical limitations that prevent robust liver volume quantification.
- Incomplete medical records, missing key baseline clinical data, or loss to follow-up.
Who the study is looking for
- Age \>= 18 years.
- Clinically or histologically confirmed unresectable hepatocellular carcinoma (HCC).
- Received immunotherapy as part of their tumor treatment regimen.
- Availability of high-quality baseline pre-treatment imaging data suitable for functional liver volume and total liver volume segmentation.
- Complete clinical and follow-up survival data.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of University of Science and Technology of China Coordinator of this site? Confirm its status | Hefei | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.